NCT02381535 2025-02-11
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
National Cancer Institute (NCI)
Phase 1 Completed
Clinical Trials
8 trialsNCT01064479 2024-07-16
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00096174 2023-06-29
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01711541 2023-06-07
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00274937 2022-10-25
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
Children's Oncology Group
Phase 3 Completed
NCT02508246 2019-03-13
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
University of Washington
Phase 1 Completed
NCT00408694 2018-01-30
Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00122460 2014-07-23
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
Merck KGaA, Darmstadt, Germany
Phase 3 Completed